{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:05:03Z","timestamp":1789877103206,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[1998,12,1]],"date-time":"1998-12-01T00:00:00Z","timestamp":912470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[1998,12]]},"DOI":"10.1007\/bf03348040","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T13:42:26Z","timestamp":1396618946000},"page":"748-752","source":"Crossref","is-referenced-by-count":54,"title":["Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-\u03b2 therapy for multiple sclerosis"],"prefix":"10.1007","volume":"21","author":[{"given":"M.","family":"Rotondi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Oliviero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Profice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Mone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Del Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mazziotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Sinisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bellastella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,29]]},"reference":[{"key":"BF03348040_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0300-483X(95)03124-X","volume":"105","author":"T Vial","year":"1995","unstructured":"Vial T., Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 105: 31, 1995.","journal-title":"Toxicology"},{"key":"BF03348040_CR2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0140-6736(85)90203-X","volume":"8946","author":"P Burman","year":"1985","unstructured":"Burman P., Karlsson F.A., Oberg K., Alm G. Autoimmune thyroid disease in interferon treated patients. Lancet 8946: 100, 1985.","journal-title":"Lancet"},{"key":"BF03348040_CR3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000184606","volume":"44","author":"C Carella","year":"1995","unstructured":"Carella C., Amato G., Biondi B., Rotondi M., Morisco F., Tuccillo C., Chiuchiolo N., Signoriello G., Caporaso N., Lombardi G. Longitudinal study of antibodies against thyroid in patients undergoing interferon-\u03b1 therapy for HCV chronic hepatitis. Horm. Res. 44: 110, 1995.","journal-title":"Horm. Res."},{"key":"BF03348040_CR4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/eje.0.1320587","volume":"132","author":"D Preziati","year":"1995","unstructured":"Preziati D., La Rosa L., Covini G., Marcelli R., Rescalli S., Persani L., Del Ninno E., Meroni P.L., Colombo M., Beck-Peccoz P. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur. J. Endocrinol. 132: 587, 1995.","journal-title":"Eur. J. Endocrinol."},{"key":"BF03348040_CR5","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0002-9343(96)00259-8","volume":"172","author":"E Roti","year":"1996","unstructured":"Roti E., Minelli R., Giuberti T., Marchelli S., Schianchi C., Gardini E., Salvi M., Fiaccadori F., Ugolotti G., Neri T.M., Braverman L.E. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am. J. Med. 172: 482, 1996.","journal-title":"Am. J. Med."},{"key":"BF03348040_CR6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2265.1996.751768.x","volume":"44","author":"M Marazuela","year":"1996","unstructured":"Marazuela M., Garc\u00eda-Buey L., Gonz\u00e1lez-Fern\u00e1ndez B., Garc\u00eda-Monz\u00f3n C., Arranz A., Borque M.J., Moreno-Otero R. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon \u03b1 therapy. Clin. Endocrinol. (Oxf.) 44: 635, 1996.","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BF03348040_CR7","first-page":"788","volume":"15","author":"AP Weetman","year":"1994","unstructured":"Weetman A.P., McGregor A.M. Autoimmune thyroid disease: Further development in our understanding. Endocr. Rev. 15: 788, 1994.","journal-title":"Endocr. Rev."},{"key":"BF03348040_CR8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/BF02806348","volume":"28","author":"K Katayama","year":"1993","unstructured":"Katayama K., Hayashi N., Takehara T., Suzuki K., Kasahara A., Fusamoto H., Kamada T. Alpha-interferon enhances gamma-interferon production of peripheral blood mononuclear cells preactivated with phytohemoagglutinin. Gastroenterol. Jpn. 28: 673, 1993.","journal-title":"Gastroenterol. Jpn."},{"key":"BF03348040_CR9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/bjc.1990.237","volume":"62","author":"G Pichert","year":"1990","unstructured":"Pichert G., Jost L.M., Zobeli L., Odermatt B., Pedio G., Stahel R.A. Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. Br. J. Cancer 62: 100, 1990.","journal-title":"Br. J. Cancer"},{"key":"BF03348040_CR10","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1177\/1352458519950101005","volume":"1","author":"M Revel","year":"1995","unstructured":"Revel M., Chebath J., Mangelus M., Harrah S., Maviglia G.A. Antagonism of interferon-beta on interferon-gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Mult. Scler. 1: S5, 1995.","journal-title":"Mult. Scler."},{"key":"BF03348040_CR11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0165-5728(95)00072-A","volume":"61","author":"A Miller","year":"1995","unstructured":"Miller A., Lanir N., Shapiro S., Revel M., Honigmon S., Kinarty A., Lahat N. Immunoregulatory effects of interferon-\u03b2 and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis and other autoimmune diseases. J. Neuroimmunol. 61: 17, 1995.","journal-title":"J. Neuroimmunol."},{"key":"BF03348040_CR12","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/jir.1990.10.559","volume":"10","author":"EC Borden","year":"1990","unstructured":"Borden E.C., Rinehart J.J., Storer B.E., Trump D.L., Paulnock D.M., Teitelbaum A.P. Biological and clinical effects of interferon-\u03b2ser at two doses. J. Interferon Res. 10: 559, 1990.","journal-title":"J. Interferon Res."},{"key":"BF03348040_CR13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","volume":"43","author":"The IFN \u03b2 Multiple Sclerosis Study Group","year":"1993","unstructured":"The IFN \u03b2 Multiple Sclerosis Study Group. Interferon beta 1-b is effective in relapsing-remitting multiple sclerosis: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655, 1993.","journal-title":"Neurology"},{"key":"BF03348040_CR14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","volume":"45","author":"The IFN \u03b2 Multiple Sclerosis Study Group","year":"1995","unstructured":"The IFN \u03b2 Multiple Sclerosis Study Group and the University of British Columbia MS\/MRI Analysis Group. Interferon beta 1-b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45: 1277, 1995.","journal-title":"Neurology"},{"key":"BF03348040_CR15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","volume":"13","author":"CM Poser","year":"1983","unstructured":"Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.A., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13: 227, 1983.","journal-title":"Ann. Neurol."},{"key":"BF03348040_CR16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke J.F. Rating neurologic impairement in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444, 1983.","journal-title":"Neurology"},{"key":"BF03348040_CR17","first-page":"399","volume":"89","author":"U Watanabe","year":"1994","unstructured":"Watanabe U., Hashimoto E., Hisamitsu T., Obata H., Hayashi N. The risk factor for development of thyroid disease during interferon-\u03b1 therapy for chronic hep atitis C. Am. J. Gastroenterol. 89: 399, 1994.","journal-title":"Am. J. Gastroenterol."},{"key":"BF03348040_CR18","first-page":"613","volume":"21","author":"BD Clifford","year":"1995","unstructured":"Clifford B.D., Donahue D., Smith L., Cable E., Luttig B., Manns M., Bonkowsky H.L. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 21: 613, 1995.","journal-title":"Hepatology"},{"key":"BF03348040_CR19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/thy.1997.7.837","volume":"7","author":"F Schuppert","year":"1997","unstructured":"Schuppert F., Rambusch E., Kirchner H., Atzpodien J., Kohn L.D., Von Zur M\u00fahlen A. Patients treated with interferon-\u03b1, interferon-\u03b2, and interleukin-2 have a different thyroid autoantibody pattern than patients suffering from endogenous autoimmune thyroid disease. Thyroid 7: 837, 1997.","journal-title":"Thyroid"},{"key":"BF03348040_CR20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1055\/s-2007-1003651","volume":"23","author":"MC Pagliacci","year":"1991","unstructured":"Pagliacci M.C., Pelicci G., Schippa M., Liberati A.M., Nicoletti I. Does Interferon-\u03b2 therapy induce thyroid autoimmune phenomena? Horm. Metab. Res. 23: 196, 1991.","journal-title":"Horm. Metab. Res."},{"key":"BF03348040_CR21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1507\/endocrj.43.545","volume":"43","author":"Y Nagai","year":"1996","unstructured":"Nagai Y., Ohsawa K., Leki Y., Kobayashi K. Effect of interferon-beta on thyroid function in patients of chronic hepatitis C without preexisting autoimmune thyroid disease. Endocr. J. 43: 545, 1996.","journal-title":"Endocr. J."},{"key":"BF03348040_CR22","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/archneur.1997.00550210095020","volume":"54","author":"SR Schwid","year":"1997","unstructured":"Schwid S.R., Goodman A.D., Mattson D.H. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch. Neurol. 54: 1169, 1997.","journal-title":"Arch. Neurol."},{"key":"BF03348040_CR23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2265.1995.tb01894.x","volume":"43","author":"MPJ Vanderpump","year":"1995","unstructured":"Vanderpump M.P.J., Tumbridge W.M.G., Frennch J.M., Appleton D., Batest D., Clark F., Grimley Evans J., Hasen D.M., Rodgers H., Tunbridge F., Young E.T. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin. Endocrinol. (Oxf.) 43: 55, 1995.","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BF03348040_CR24","first-page":"1439","volume":"77","author":"K Yamazaki","year":"1993","unstructured":"Yamazaki K., Kanaji Y., Shizume K., Yamakawa Y., Demura H., Kanaii Y., Obara T., Sato K. Reversible inhibition by interferons alpha and beta of 125I incorporation and thyroid hormone release by human thyroid follicles in vitro. J. Clin. Endocrinol. Metab. 77: 1439, 1993.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03348040_CR25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199104043241403","volume":"324","author":"K Hashizume","year":"1991","unstructured":"Hashizume K., Ichikawa K., Sakurai A., Suzuki S., Takeda T., Kobayashi M., Miyamoto T., Arai M., Nagasawa T. Administration of thyroxine in treated Graves\u2019 disease. N. Engl. J. Med. 324: 947, 1991.","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03348040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03348040\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03348040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:45:17Z","timestamp":1746171917000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03348040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1998,12]]}},"alternative-id":["BF03348040"],"URL":"https:\/\/doi.org\/10.1007\/bf03348040","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,12]]}}}